REVIEW ARTICLE
Hematopoietic stem cell transplantation and acute kidney injury in children: A comprehensive review
Rupesh Raina,
Nicholas Herrera,
Vinod Krishnappa,
Sidharth Kumar Sethi,
Akash Deep,
Wei-Ming Kao,
Timothy Bunchman,
Rolla Abu-Arja,
Corresponding Author
Rupesh Raina
Department of Pediatric Nephrology, Akron Children's Hospital, Akron, OH, USA
Correspondence
Rupesh Raina, MD, FAAP, FACP, FASN, FNKF Adult-Pediatric Kidney Disease/Hypertension, Department of Nephrology, Cleveland Clinic Akron General and Akron Children's Hospital, Akron, OH, USA.
Emails: [email protected] and [email protected]
Search for more papers by this authorNicholas Herrera
Department of Pediatrics-Nephrology, UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA
Search for more papers by this authorVinod Krishnappa
Cleveland Clinic Akron General/Akron Nephrology Associates, Akron, OH, USA
Search for more papers by this authorSidharth Kumar Sethi
Kidney and Urology Institute, Medanta, The Medicity Hospital, Gurgaon, Haryana, India
Search for more papers by this authorAkash Deep
Department of Paediatric Intensive Care, King's College Hospital, London, UK
Search for more papers by this authorWei-Ming Kao
Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA
Search for more papers by this authorTimothy Bunchman
Children's Hospital of Richmond, VCU School of Medicine, Richmond, VA, USA
Search for more papers by this authorRolla Abu-Arja
Department of Pediatric Hematology & Oncology Pediatrics, Nationwide Children's Hospital/Ohio State University, Columbus, OH, USA
Search for more papers by this authorRupesh Raina,
Nicholas Herrera,
Vinod Krishnappa,
Sidharth Kumar Sethi,
Akash Deep,
Wei-Ming Kao,
Timothy Bunchman,
Rolla Abu-Arja,
Corresponding Author
Rupesh Raina
Department of Pediatric Nephrology, Akron Children's Hospital, Akron, OH, USA
Correspondence
Rupesh Raina, MD, FAAP, FACP, FASN, FNKF Adult-Pediatric Kidney Disease/Hypertension, Department of Nephrology, Cleveland Clinic Akron General and Akron Children's Hospital, Akron, OH, USA.
Emails: [email protected] and [email protected]
Search for more papers by this authorNicholas Herrera
Department of Pediatrics-Nephrology, UH Rainbow Babies and Children's Hospital, Cleveland, OH, USA
Search for more papers by this authorVinod Krishnappa
Cleveland Clinic Akron General/Akron Nephrology Associates, Akron, OH, USA
Search for more papers by this authorSidharth Kumar Sethi
Kidney and Urology Institute, Medanta, The Medicity Hospital, Gurgaon, Haryana, India
Search for more papers by this authorAkash Deep
Department of Paediatric Intensive Care, King's College Hospital, London, UK
Search for more papers by this authorWei-Ming Kao
Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA
Search for more papers by this authorTimothy Bunchman
Children's Hospital of Richmond, VCU School of Medicine, Richmond, VA, USA
Search for more papers by this authorRolla Abu-Arja
Department of Pediatric Hematology & Oncology Pediatrics, Nationwide Children's Hospital/Ohio State University, Columbus, OH, USA
Search for more papers by this authorAbstract
AKI in the setting of HSCT is commonly investigated among adult patients. In the same way, malignancies requiring treatment with HSCT are not limited to the adult patient population, AKI following HSCT is frequently encountered within pediatric patient populations. However, inadequate information regarding epidemiology and pathophysiology specific to pediatric patients prevents development of appropriate and successful therapeutic strategies for those afflicted. Addressing AKI in the context of sinusoidal obstruction syndrome, chemotherapy, thrombotic microangiopathy and hypertension post chemotherapy, glomerulonephritis, and graft versus host disease provides greater insight into renal impairment associated with these HSCT-related ailments. To obtain a better understanding of AKI among pediatric patients receiving HSCT, we investigated the current literature specifically addressing these areas of concern.
References
- 1Park B, Yoo KH, Kim C. Hematopoietic stem cell expansion and generation: the ways to make a breakthrough. Blood Res. 2015; 50: 194-203.
- 2Pasquini M, Wang Z, Schneider L. Current use and outcome of hematopoietic stem cell transplantation: Part I CIBMTR summary slides. CIBMTR Newsletter [serial online]. 2009; 15: 7-11.
- 3 National Marrow Donor Program/Be the Match 2012 report to the community; 2012. Available from: https://bethematch.org/workarea/downloadasset.aspx?id=1985.
- 4Bunchman T. Stem cell transplantation and renal replacement therapy: new predictors of outcome. Pediatr Crit Care Med. 2010; 11: 754-755.
- 5Hazar V, Gungor O, Guven AG, et al. Renal function after hematopoietic stem cell transplantation in children. Pediatric Blood & Cancer 2009; 53: 197-202.
- 6Kist-van Holthe JE, Goedvolk CA, Brand R, et al. Prospective study of renal insufficiency after bone marrow transplantation. Pediatr Nephrol. 2002; 17: 1032-1037.
- 7Patzer L, Kentouche K, Ringelmann F, Misselwitz J. Renal function following hematological stem cell transplantation in childhood. Pediatr Nephrol. 2003; 18: 623-635.
- 8Kist-van Holthe JE, van Zwet JM, Brand R, van Weel MH, Vossen JM, van der Heijden AJ. Bone marrow transplantation in children: consequences for renal function shortly after and 1 year post-BMT. Bone Marrow Transplant. 1998; 22: 559-564.
- 9Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989; 13: 210-216.
- 10Myers KC, Lawrence J, Marsh RA, Davies SM, Jodele S. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2013; 19: 500-503.
- 11Grönroos M, Bolme P, Winiarski J, Berg U. Long-term renal function following bone marrow transplantation. Bone Marrow Transplant. 2007; 39: 717-723.
- 12Patzer L, Ringelmann F, Kentouche K, et al. Renal function in long-term survivors of stem cell transplantation in childhood. A prospective trial. Bone Marrow Transplant. 2001; 27: 319-327.
- 13Esiashvili N, Chiang KY, Hasselle MD, Bryant C, Riffenburgh RH, Paulino AC. Renal toxicity in children undergoing total body irradiation for bone marrow transplant. Radiother Oncol. 2009; 90: 242-246.
- 14Fish JD, Grupp SA. Stem cell transplantation for neuroblastoma. Bone Marrow Transplant. 2008; 41: 159-165.
- 15Fadia A, Casserly LF, Sanchorawala V, et al. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int. 2003; 63: 1868-1873.
- 16Michael M, Shimoni A, Nagler A. Regulatory T cells in allogeneic stem cell transplantation. Clin Dev Immunol. 2013; 2013: 608951.
- 17Yamada N, Urahashi T, Ihara Y, et al. Veno-occlusive disease/sinusoidal obstruction syndrome associated with potential antibody-mediated rejection after pediatric living donor liver transplantation: a case report. Transplant Proc. 2012; 44: 810-813.
- 18Humphreys BD, Soiffer RJ, Magee CC. Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol. 2005; 16: 151-161.
- 19Lopes JA, Jorge S. Acute kidney injury following HCT: incidence, risk factors and outcome. Bone Marrow Transplant. 2011; 46: 1399-1408.
- 20Baron F, Deprez M, Beguin Y. The veno-occlusive disease of the liver. Haematologica. 1997; 82: 718-725.
- 21Mori J, Ohashi K, Yamaguchi T, et al. Risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on Acute Kidney Injury Network criteria. Intern Med. 2012; 51: 2105-2110.
- 22Yu ZP, Ding JH, Chen BA, et al. Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation. Chin J Cancer. 2010; 29: 946-951.
- 23Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007; 40: 935-944.
- 24Ileri T, Ertem M, Ozcakar ZB, et al. Prospective evaluation of acute and chronic renal function in children following matched related donor hematopoietic stem cell transplantation. Pediatr Transplant. 2010; 14: 138-144.
- 25Santoso JT, Lucci JA, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003; 52: 13-18.
- 26Fink JC, Cooper MA, Burkhart KM, McDonald GB, Zager RA. Marked enzymuria after bone marrow transplantation: a correlate of veno-occlusive disease-induced “hepatorenal syndrome”. J Am Soc Nephrol. 1995; 6: 1655-1660.
- 27Hingorani S, Guthrie KA, Schoch G, Weiss NS, McDonald GB. Chronic kidney disease in long-term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007; 39: 223-229.
- 28Weiss AS, Sandmaier BM, Storer B, Storb R, McSweeney PA, Parikh CR. Chronic kidney disease following non-myeloablative hematopoietic cell transplantation. Am J Transplant. 2006; 6: 89-94.
- 29McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993; 118: 255-267.
- 30Goldstein SL, Somers MJ, Baum MA, et al. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. Kidney Int. 2005; 67: 653-658.
- 31Keates-Baleeiro J, Moore P, Koyama T, Manes B, Calder C, Frangoul H. Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant. 2006; 38: 285-289.
- 32Sethi SK, Bunchman T, Raina R, Kher V. Unique considerations in renal replacement therapy in children: core curriculum 2014. Am J Kidney Dis. 2014; 63: 329-345.
- 33Goldstein SL. Acute kidney injury in children: prevention, treatment and rehabilitation. Contrib Nephrol. 2011; 174: 163-172.
- 34Flores FX, Brophy PD, Symons JM, et al. Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. Pediatr Nephrol. 2008; 23: 625-630.
- 35Ronco C, Bellomo R, Homel P, et al. Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet. 2000; 356: 26-30.
- 36Leu L, Baribeault D. A comparison of the rates of cisplatin (cDDP)-induced nephrotoxicity associated with sodium loading or sodium loading with forced diuresis as a preventative measure. J Oncol Pharm Pract. 2010; 16: 167-171.
- 37Farry JK, Flombaum CD, Latcha S. Long term renal toxicity of ifosfamide in adult patients–5 year data. Eur J Cancer. 2012; 48: 1326-1331.
- 38Colby C, Koziol S, McAfee SL, Yeap B, Spitzer TR. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant. Bone Marrow Transplant. 2002; 29: 467-472.
- 39Foreman NK, Schissel D, Le T, et al. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol. 2005; 71: 181-187.
- 40Locatelli F, Pession A, Bonetti F, et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia. 1994; 8: 844-849.
- 41Rehman MU, Tahir M, Ali F, et al. Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid. Mol Cell Biochem. 2012; 365: 119-127.
- 42Srivastava A, Bradstock KF, Szer J, de Bortoli L, Gottlieb DJ. Busulphan and melphalan prior to autologous bone marrow transplantation. Bone Marrow Transplant. 1993; 12: 323-329.
- 43Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009; 4: 481-508.
- 44Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex Heart Inst J. 2011; 38: 263-265.
- 45Aparicio-Gallego G, Afonso-Afonso FJ, León-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs. 2011; 22: 1-8.
- 46Dhaun N, Webb DJ. Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? Hypertension. 2010; 56: 575-577.
- 47Kone BC, Whelton A, Santos G, Saral R, Watson AJ. Hypertension and renal dysfunction in bone marrow transplant recipients. Q J Med. 1988; 69: 985-995.
- 48Loughran TP Jr, Deeg HJ, Dahlberg S, Kennedy MS, Storb R, Thomas ED. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol. 1985; 59: 547-553.
- 49Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000; 18: 2169-2178.
- 50Halevy D, Radhakrishnan J, Markowitz G, Appel G. Thrombotic microangiopathies Crit Care Clin. 2002; 18: 309-320, vi.
- 51Helms RA, Quan DJ. Textbook of Therapeutics: Drug and Disease Management. Philadelphia, PA: Lippincott Williams & Wilkins; 2006.
- 52Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood. 2011; 118: 1452-1462.
- 53Stavrou E, Lazarus HM. Thrombotic microangiopathy in haematopoietic cell transplantation: an update. Mediterr J Hematol Infect Dis. 2010; 2: e2010033.
- 54Ricci Z, Ronco C. Year in review 2008: critical care–nephrology. Crit Care. 2009; 13: 227.
- 55Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009; 9: 1876-1885.
- 56Dagenais NJ, Jamali F. Protective effects of angiotensin II interruption: evidence for antiinflammatory actions. Pharmacotherapy. 2005; 25: 1213-1229.
- 57Stypmann J, Engelen MA, Orwat S, et al. Cardiovascular characterization of Pkd2(+/LacZ) mice, an animal model for the autosomal dominant polycystic kidney disease type 2 (ADPKD2). Int J Cardiol. 2007; 120: 158-166.
- 58Lin J, Valeri AM, Markowitz GS, D'Agati VD, Cohen DJ, Radhakrishnan J. Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation. 2002; 73: 783-788.
- 59Okano M, Sakata N, Ueda S, Takemura T. Recovery from life-threatening transplantation-associated thrombotic microangiopathy using eculizumab in a patient with very severe aplastic anemia. Bone Marrow Transplant. 2014; 49: 1116-1118.
- 60Jodele S, Fukuda T, Vinks A, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant. 2014; 20: 518-525.
- 61Terrier B, Delmas Y, Hummel A, et al. Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects. Nephrol Dial Transplant. 2007; 22: 1369-1376.
- 62Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002; 346: 2053-2060.
- 63Kimura S, Horie A, Hiki Y, et al. Nephrotic syndrome with crescent formation and massive IgA deposition following allogeneic bone marrow transplantation for natural killer cell leukemia/lymphoma. Blood. 2003; 101: 4219-4221.
- 64Suehiro T, Masutani K, Yokoyama M, et al. Diffuse proliferative glomerulonephritis after bone marrow transplantation. Clin Nephrol. 2002; 58: 231-237.
- 65Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis. 2007; 2: 35.
- 66Ball LM, Egeler RM. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008; 41(suppl 2): S58-S64.
- 67Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003; 101: 2440-2445.
- 68Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med. 1990; 322: 485-494.
- 69Theurich S, Fischmann H, Shimabukuro-Vornhagen A, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev. 2012; CD009159.
- 70Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999; 5: 347-356.
- 71Corvo R, Paoli G, Barra S, et al. Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant. Int J Radiat Oncol Biol Phys. 1999; 43: 497-503.
- 72Ferrara JL, Cooke KR, Teshima T. The pathophysiology of acute graft-versus-host disease. Int J Hematol. 2003; 78: 181-187.
- 73Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood. 2007; 110: 3804-3813.
- 74Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008; 134-141.
- 75Ho VT, Soiffer RJ. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001; 98: 3192-3204.
- 76Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood. 2005; 106: 3308-3313.
- 77Detaille T, Anslot C, de Clety SC. Acute kidney injury in paediatric bone marrow patients. Acta Clin Belg Suppl. 2007; 2: 401-404.
10.1179/acb.2007.090 Google Scholar
- 78Goldstein SL, Devarajan P. Progression from acute kidney injury to chronic kidney disease: a pediatric perspective. Adv Chronic Kidney Dis. 2008; 15: 278-283.
- 79Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 2012; 82: 516-524.
- 80Ellis MJ, Parikh CR, Inrig JK, Kanbay M, Patel UD. Chronic kidney disease after hematopoietic cell transplantation: a systematic review. Am J Transplant. 2008; 8: 2378-2390.
- 81Antignac C, Gubler MC, Leverger G, Broyer M, Habib R. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation. Kidney Int. 1989; 35: 1336-1344.
- 82Hingorani S. Chronic kidney disease after liver, cardiac, lung, heart-lung, and hematopoietic stem cell transplant. Pediatr Nephrol. 2008; 23: 879-888.
- 83Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006; 12: 138-151.
- 84Cohen EP, Drobyski WR, Moulder JE. Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007; 39: 571-572.
- 85Cohen EP, Piering WF, Kabler-Babbitt C, Moulder JE. End-stage renal disease (ESRD) after bone marrow transplantation: poor survival compared to other causes of ESRD. Nephron. 1998; 79: 408-412.
- 86Thomas SE, Hutchinson RJ, DebRoy M, Magee JC. Successful renal transplantation following prior bone marrow transplantation in pediatric patients. Pediatr Transplant. 2004; 8: 507-512.
- 87Hamawi K, De Magalhaes-Silverman M, Bertolatus JA. Outcomes of renal transplantation following bone marrow transplantation. Am J Transplant. 2003; 3: 301-305.
- 88Butcher JA, Hariharan S, Adams MB, Johnson CP, Roza AM, Cohen EP. Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin Transplant. 1999; 13: 330-335.
- 89Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341: 1725-1730.
- 90 National Clinical Guideline Centre, National Institute for Health and Clinical Excellence. Guidance, in Acute Kidney Injury: Prevention, Detection and Management Up to the Point of Renal Replacement Therapy. London: Royal College of Physicians (UK), National Clinical Guideline Centre; 2013.
- 91Noel C, Hazzan M, Noel-Walter MP, Jouet JP. Renal failure and bone marrow transplantation. Nephrol Dial Transplant. 1998; 13: 2464-2466.
- 92Bao YS, Xie RJ, Wang M, Feng SZ, Han MZ. An evaluation of the RIFLE criteria for acute kidney injury after myeloablative allogeneic haematopoietic stem cell transplantation. Swiss Med Wkly. 2011; 141: w13225.
- 93Lu R, Mucino-Bermejo MJ, Armignacco P, et al. Survey of acute kidney injury and related risk factors of mortality in hospitalized patients in a third-level urban hospital of Shanghai. Blood Purif. 2014; 38: 140-148.
- 94Lu RH, Fang Y, Gao JY, et al. Analysis of incidence and risk factor in hospitalized patients with acute kidney injury. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2011; 23: 413-417.
Citing Literature
